BX-471 Berlex.

Area of Science:

• Pharmacology
• Immunology
• Neurology

Background:

• Berlex and Schering AG are developing BX-471, a novel non-peptide chemokine receptor 1 (CCR1) antagonist.
• BX-471 is the lead compound in a series targeting autoimmune diseases, with a specific focus on multiple sclerosis (MS).

Purpose of the Study:

• To evaluate the safety and efficacy of BX-471 in patients with autoimmune diseases, particularly MS.
• To advance BX-471 through clinical trials for potential therapeutic applications.

Main Methods:

• BX-471 underwent Phase I clinical trials for autoimmune diseases starting in March 2000.
• Phase I trials in MS patients were ongoing as of March 2002, with positive results reported.
• Planning for Phase II trials in MS patients was underway by mid-March 2002.

Main Results:

• Positive results from Phase I trials have been reported, indicating potential therapeutic benefits.
• BX-471 demonstrated tolerability and safety in early-stage clinical investigations.
• The compound is progressing towards later-stage clinical evaluation.

Conclusions:

• BX-471 shows promise as a treatment for autoimmune diseases, especially MS.
• Further clinical development, including Phase II trials, is warranted to confirm efficacy and safety.
• BX-471 represents a potential new therapeutic option for managing MS and other inflammatory conditions.